Atrial Defibrillators: What's Their Role?

Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982;306:1018–1022. Wijfffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995;92:1954–1968. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation of less than 48 hours' duration. Ann Intern Med 1997;126: 615–620. Lau CP, Tse HF, Lok NS, Lee KL, Ho DS, Sopher M, Murgatroyd F, Camm AJ. Initial clinical experience with an implantable human atrial defibrillation. Pacing Clin Electrophysiol 1997;20:220–225. Cooper RAS, Alferness CA, Smith WM, Ideker RE. Internal cardioversion of atrial fibrillation in sheep. Circulation 1993;87:1673–1686. Murgatroyd FD, Slade AKB, Sopher SM, Rowland E, Ward DE, Camm AJ. Efficacy and tolerability of low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol 1995;25: 1347–1353. Lok NS, Lau CP, Ho DSW, Tang YW. Hemodynamic effects and clinical determinants of defibrillation threshold for low energy transvenous atrial defibrillation in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol 1997;20:899–908. Levy S, Richard P, Lau CP, Lok NS, Camm AJ, Murgatroyd FD, Jordaens LJ, Kappenberger LJ, Brugada P, Riply KL. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol 1997;27:750–755. Saksena S, Prakash A, Mangeon L, Varanasi S, Kolettis T, Mathew P, De Groot P, Mehra R, Krol RB. Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations.Am J Cardiol 1995;76:913–921. Ayers GM, Alferness CA, Ilina MB, Wagner DO, Sirokman WA, Adams JM, Griffin JC. Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation 1994;89:413–422. Murgatroyd FD, Johnson EE, Cooper RA, Lau CP, Alt E, Kappenburger LJ, Smith JM, Camm AJ, Wharton JM. Safety of low energy transvenous atrial defibrillation: World experience. Circulation 1994;90:14 (abstract). Lok NS, Lau CP, Tse HF, Ayers GM. Clinical shock tolerability and effect of different right atrial electrode locations on efficacy of low energy human transvenous atrial defibrillation using an implantable lead system. J Am Coll Cardiol 1997;30: 1324–1330. Ayers GM. How can atrial defibrillation be made more tolerable? In: Murgatroyd FD, Camm AJ (eds). Nonpharmacological Management of Atrial Fibrillation. Armonk, NY: Futura Publishing Co., 1997:474–487. Tse HF, Lau CP, Sra JS, Crijns HJGM, Edvardsson N, Kacet S, Wyse GD, for the Metrix Investigators. Atrial fibrillation detection and R wave synchronization by Metrix implantable atrial defibrillator: Implication for long term efficacy and safety. Circulation 1999;99:1446–1451. Wellens HJJ, Lau CP, Lüderitz B, Akhtar M, Waldo AL, Camm AJ, Timmermans C, Tse HF, Jung W, Jordaens L, Ayers G, for the Metrix Investigators. Atrioverter, an implantable device for the treatment of atrial fibrillation. Circulation 1998;98:1651–1656. Tse HF, Lau CP, Yu CM, Lee KLF, Michaud GF, Knight BP, Morady F, Strickberger SA. Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation. J Cardiovasc Electrophysiol 1999;10:1200–1209. Timmermans C, Levy S, Ayers GM, Jung W, Jordaens L, Rosenqvist M, Thibault B, Camm J, Rodriguez LM, Wellens HJ. Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: Observations on treated and nontreated episodes. Metrix Investigators. J Am Coll Cardiol 2000;35:1428–1433. Tse HF, Wang Q, Yu CM, Ayers GM, Lau CP. Time course of recovery of left atrial mechanical dysfunction after cardioversion of spontaneous atrial fibrillation with the implantable atrial defibrillator. Am J Cardiol 2000;86:1023–1025. Daoud EG, Timmermans C, Fellows C, Hoyt R, Lemery R, Dawson K, Ayers GM, for the Metrix Investigators. Initial clinical experience with ambulatory use of an implantable atrial defibrillator for conversion of atrial fibrillation. Circulation 2000;102:1407–1413. Jung W, Luderitz B. Implantation of a new arrhythmia management system in patients with supraventricular and ventricular tachyarrhythmias. Lancet 1997;349:853–854. Jung W, Wolpert C, Esmailzadeh B, Spehl S, Herwig S, Schumacher B, Lewalter T, Omran H, Schimpf R. Vahlhaus C, Welz A, Luderitz B. Clinical experience with implantable atrial and combined atrioventricular defibrillators. J Interv Card Electrophysiol 2000;4:185–195. Gold MR, Daubert JP, Peters RW, Shorofsky SR. A clinical trial of a combined atrial and ventricular defibrillator in patients without ventricular arrhythmias. J Am Coll Cardiol 2000;35:115A (abstract). Timmermans C, Rodriguez LM, Smeets JLRM, Wellens HJJ. Immediate reinitiation of atrial fibrillation following internal atrial defibrillation. J Cardiovasc Electrophysiol 1998;9:122–128. Tse HF, Lau CP, Ayers GM. The incidence and modes of onset of spontaneous re-initiation of atrial fibrillation following successful internal cardioversion and its prevention by intravenous sotalol. Heart 1999;82:319–324. Tse HF, Lau CP, Ayers GM. Atrial pacing for suppression of early re-initiation of atrial fibrillation after successful internal cardioversion. Eur Heart J 21:1167–1176. Lau CP, Tse HF, Ayers GM. Defibrillation guided radiofrequency ablation of atrial fibrillation secondary to an atrial focus. J Am Coll Cardiol 1999;33:1217–1226. Lau CP, Lok NS. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. Pacing Clin Electrophysiol 1997;20:1–11.